IND-enabling studies underway; awarded $30.8M by ARPA-H PROSPR program (Feb 2026) for Phase 1 entry.
Updated 24 Feb 2026Checked 10 Oct0 updates this week
mTORC1 is the cell's nutrient sensor. In aging, dysregulation of mTORC1 contributes to metabolic decline.
mTOR forms two complexes (mTORC1, mTORC2). Rapamycin blocks both; TOR-101 selectively blocks mTORC1 only.
Intrinsic capacity is physical and mental capability to function independently. Preserving it means maintaining muscle, bone, metabolism and cognition.
| Spec | TOR-101 |
|---|---|
| Target mechanism | mTORC1 selective inhibitionR (reported) |
| mTORC2 activity | Minimal (major safety advantage vs rapamycin)R (reported) |
| Rat max tolerated dose | >250 mg/kg (vs 0.5 mg/kg for everolimus)R (reported) |
| Monkey safety | No toxicity observedR (reported) |
R reported by the company
Cambrian Bio
Group of aging biotechs, rapamycin-like drugs
New York company founded by James Peyer that starts and funds a group of small biotechs, each attacking one cause of aging through a specific disease, such as better versions of the drug rapamycin.
